Literature DB >> 20506124

Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.

Fernando Perez-Ruiz1, Samuel Hernandez-Baldizon, Ana M Herrero-Beites, Miguel A Gonzalez-Gay.   

Abstract

OBJECTIVE: To find factors associated with the development of renal colic during uricosuric therapy.
METHODS: We performed a prospective cohort followup study of patients with gout and no previous history of kidney stones who had been treated with uricosurics. Clearance of creatinine and urate, 24-hour urinary uric acid (UA), undissociated urinary UA concentration, 24-hour undissociated urinary UA, and pH and urine sediment were obtained. Cox proportional hazards regression analysis was used to identify variables associated with renal colic as the outcome. The rate of renal colic was compared with that of control patients receiving allopurinol who had no previous history of renal stones.
RESULTS: We analyzed a 784 patient-year exposure from 216 patients: 206 with renal underexcretion of UA and 10 with normal excretion. There were 21 clinical events. Two variables showed increased risk hazard for developing lithiasis: clearance of UA at baseline and undissociated urinary UA concentration during followup. When only patients with underexcretion of UA were included in the analysis, undissociated urinary UA during followup remained the only statistically significant variable. Patients who showed an undissociated UA concentration < 20 mg/dl did not show an increase in the rate of lithiasis or events compared with patients receiving allopurinol.
CONCLUSION: Clearance of UA at baseline may be useful for selecting patients suitable for uricosuric treatment. The estimation of the concentration of undissociated urinary UA is useful for evaluating the risk of lithiasis during followup.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20506124     DOI: 10.1002/acr.20221

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  9 in total

1.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

2.  Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.

Authors:  Nicola Dalbeth; Graeme Jones; Robert Terkeltaub; Dinesh Khanna; Jeff Kopicko; Nihar Bhakta; Scott Adler; Maple Fung; Chris Storgard; Scott Baumgartner; Fernando Perez-Ruiz
Journal:  Arthritis Rheumatol       Date:  2017-08-04       Impact factor: 10.995

3.  Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).

Authors:  Thomas Bardin; Robert T Keenan; Puja P Khanna; Jeff Kopicko; Maple Fung; Nihar Bhakta; Scott Adler; Chris Storgard; Scott Baumgartner; Alexander So
Journal:  Ann Rheum Dis       Date:  2016-11-07       Impact factor: 19.103

4.  Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats.

Authors:  Muzaffar Iqbal; Essam Ezzeldin; Rashed Naji Herqash; Ozair Alam
Journal:  PLoS One       Date:  2019-03-14       Impact factor: 3.240

5.  Chemical Analysis of Eruca sativa Ethanolic Extract and Its Effects on Hyperuricaemia.

Authors:  Arthur Ferrari Teixeira; Jacqueline de Souza; Douglas Daniel Dophine; José Dias de Souza Filho; Dênia Antunes Saúde-Guimarães
Journal:  Molecules       Date:  2022-02-23       Impact factor: 4.411

6.  Effects of elevated serum urate on cardiometabolic and kidney function markers in a randomised clinical trial of inosine supplementation.

Authors:  Nicola Dalbeth; Borislav Mihov; Angela Stewart; Gregory D Gamble; Tony R Merriman; David Mount; Ian R Reid; Lisa K Stamp; Anne Horne
Journal:  Sci Rep       Date:  2022-07-28       Impact factor: 4.996

Review 7.  Physiology of Hyperuricemia and Urate-Lowering Treatments.

Authors:  Caroline L Benn; Pinky Dua; Rachel Gurrell; Peter Loudon; Andrew Pike; R Ian Storer; Ciara Vangjeli
Journal:  Front Med (Lausanne)       Date:  2018-05-31

8.  DKB114, A Mixture of Chrysanthemum Indicum Linne Flower and Cinnamomum Cassia (L.) J. Presl Bark Extracts, Improves Hyperuricemia through Inhibition of Xanthine Oxidase Activity and Increasing Urine Excretion.

Authors:  Young-Sil Lee; Seung-Hyung Kim; Heung Joo Yuk; Dong-Seon Kim
Journal:  Nutrients       Date:  2018-09-28       Impact factor: 5.717

9.  Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers.

Authors:  Keisuke Motoki; Takako Igarashi; Koichi Omura; Hiroshi Nakatani; Takashi Iwanaga; Ikumi Tamai; Tetsuo Ohashi
Journal:  Pharmacol Res Perspect       Date:  2019-11-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.